Can a single drug calm inflamed arteries in people with a common gene change?

NCT ID NCT06691217

First seen Oct 31, 2025 · Last updated May 11, 2026 · Updated 27 times

Summary

This study tests whether the drug canakinumab can lower inflammation in the blood vessels of people who have had a heart attack or stent, and who may also have a specific genetic change called TET2. About 120 adults will receive either canakinumab or a placebo. The main goal is to see if the drug reduces signs of inflammation around the heart arteries, which could help manage heart disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VASCULAR INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.